These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9310957)

  • 21. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequent downregulation or loss of CD79a expression in plasma cell myelomas: potential clue for diagnosis.
    Tanaka T; Ichimura K; Sato Y; Takata K; Morito T; Tamura M; Kondo E; Ohara N; Yanai H; Sakai M; Takahashi S; Yoshino T
    Pathol Int; 2009 Nov; 59(11):804-8. PubMed ID: 19883431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
    Kuroda Y; Sakai A; Tsuyama N; Katayama Y; Munemasa S; Asaoku H; Okikawa Y; Nakaju N; Mizuno M; Ogawa K; Nishisaka T; Matsui H; Tanaka H; Kimura A
    Int J Oncol; 2008 Dec; 33(6):1201-13. PubMed ID: 19020753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclin D1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry.
    Zukerberg LR; Yang WI; Arnold A; Harris NL
    Am J Clin Pathol; 1995 Jun; 103(6):756-60. PubMed ID: 7540362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coordinated expression of cyclin D1 and LEF-1/TCF transcription factor is restricted to a subset of hepatocellular carcinoma.
    Schmitt-Graeff A; Ertelt-Heitzmann V; Allgaier HP; Olschewski M; Nitschke R; Haxelmans S; Koelble K; Behrens J; Blum HE
    Liver Int; 2005 Aug; 25(4):839-47. PubMed ID: 15998435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A study on the prognostic value of cyclins D1 and E expression levels in resectable gastric cancer and on some correlations between cyclins expression, histoclinical parameters and selected protein products of cell-cycle regulatory genes.
    Tenderenda M
    J Exp Clin Cancer Res; 2005 Sep; 24(3):405-14. PubMed ID: 16270527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 20q13 and cyclin D1 in ovarian carcinomas. Analysis by fluorescence in situ hybridization.
    Diebold J; Mösinger K; Peiro G; Pannekamp U; Kaltz C; Baretton GB; Meier W; Löhrs U
    J Pathol; 2000 Apr; 190(5):564-71. PubMed ID: 10727982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cell cycle regulators in bladder cancer: relationship to schistosomiasis.
    Eissa S; Ahmed MI; Said H; Zaghlool A; El-Ahmady O
    IUBMB Life; 2004 Sep; 56(9):557-64. PubMed ID: 15590562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical evaluation of cyclin D1 in breast cancer.
    Bilalović N; Vranić S; Basić H; Tatarević A; Selak I
    Croat Med J; 2005 Jun; 46(3):382-8. PubMed ID: 15861516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of cyclin D1 protein expression in splenic marginal zone lymphoma.
    Savilo E; Campo E; Mollejo M; Pinyol M; Piris MA; Zukerberg LR; Yang WI; Koelliker DD; Nguyen PL; Harris NL
    Mod Pathol; 1998 Jul; 11(7):601-6. PubMed ID: 9688179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2.
    Chuang SS; Huang WT; Hsieh PP; Tseng HH; Campo E; Colomer D; Ye H; Lu CL; Chang HM; Cho CY; Huang SH; Lu YC; Wu JD
    Pathol Int; 2006 Aug; 56(8):440-8. PubMed ID: 16872438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclin D1 expression in primary thyroid carcinomas.
    Sporny S; Slowinska-Klencka D; Ratynska M
    Neuro Endocrinol Lett; 2005 Dec; 26(6):815-8. PubMed ID: 16380680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression patterns of cyclins D1, E in laryngeal epithelial lesions: correlation with other cell cycle regulators (p53, pRb, Ki-67 and PCNA) and clinicopathological features.
    Ioachim E; Peschos D; Goussia A; Mittari E; Charalabopoulos K; Michael M; Salmas M; Vougiouklakis T; Assimakopoulos D; Agnantis NJ
    J Exp Clin Cancer Res; 2004 Jun; 23(2):277-83. PubMed ID: 15354413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alterations of the p16/Rb/cyclin-D1 pathway in vulvar carcinoma, vulvar intraepithelial neoplasia, and lichen sclerosus.
    Lerma E; Esteller M; Herman JG; Prat J
    Hum Pathol; 2002 Nov; 33(11):1120-5. PubMed ID: 12454817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
    Ioachim E
    Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical study of cell cycle-associated proteins in adenocarcinoma of the uterine cervix treated with radiotherapy alone: P53 status has a strong impact on prognosis.
    Suzuki Y; Nakano T; Kato S; Ohno T; Tsujii H; Oka K
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):231-6. PubMed ID: 15337561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information.
    Shinozaki H; Ozawa S; Ando N; Tsuruta H; Terada M; Ueda M; Kitajima M
    Clin Cancer Res; 1996 Jul; 2(7):1155-61. PubMed ID: 9816282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis.
    Kremer M; Ott G; Nathrath M; Specht K; Stecker K; Alexiou C; Quintanilla-Martinez L; Fend F
    J Pathol; 2005 Jan; 205(1):92-101. PubMed ID: 15586381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of PRAD1/cyclin D1 in plasma cell malignancy: incidence and prognostic aspects.
    Sonoki T; Hata H; Kuribayashi N; Yoshida M; Harada N; Nagasaki A; Kimura T; Matsuno F; Mitsuya H; Matsuzaki H
    Br J Haematol; 1999 Mar; 104(3):614-7. PubMed ID: 10086803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma cell neoplasms presenting with masses: a study on morphology, expression of CD56 and cyclin D1, and presence of Epstein-Barr virus in 39 Thai patients in SiriraJ Hospital.
    Pipatsakulroj W; Pradniwat K; Treetipsatit J
    J Med Assoc Thai; 2013 Dec; 96(12):1583-91. PubMed ID: 24511724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.